Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 5/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899723 | 0.82 | CASP1 (0.50) | CASP1 | |
| SCHEMBL5899687 | 0.81 | CASP1 (0.51) | CASP1MAOB | |
| SCHEMBL5899743 | 0.81 | CASP1 (0.49) | CASP1MAOB | |
| SCHEMBL6727952 | 0.79 | CASP1 (0.56) | CASP1MAOBKDM1A | |
| SCHEMBL5899753 | 0.78 | CASP1 (0.54) | CASP1MAOB | |
| SCHEMBL5899710 | 0.78 | CASP1 (0.54) | CASP1 | |
| SCHEMBL5899797 | 0.77 | CASP1 (0.55) | CASP1MAOBKDM1A | |
| SCHEMBL5899646 | 0.76 | CASP1 (0.33) | CASP1MAOB | |
| SCHEMBL5899784 | 0.75 | MAOB (0.45) | MAOBALOX5GSTO1 | |
| SCHEMBL30041884 | 0.74 | CASP1 (0.56) | CASP1MAOBKIF11TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | claimed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | claimed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | claimed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | claimed |
| US-6995261-B2 | 4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | disclosed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | disclosed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | IL6ST, IL1RN, IL1R1 | CASP1 117/4885MAOB 1518/4885KIF11 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.